Ben has a broad range of experience in assisting clients with issues relating to corporations and securities law, with a particular focus on public and private capital raisings, mergers and acquisitions and restructures.
Ben has assisted clients across a range of sectors including financial services, life sciences, technology, food and agribusiness, health and resources including ASX listed and large unlisted public companies, small to large proprietary companies and owner managed businesses.
His expertise includes assisting clients with capital raisings (both IPOs and secondary raisings – including placements, rights issues and share purchase plans), unregulated mergers and acquisitions, including due diligence and deal implementation, and corporate reconstructions, including via court approved schemes of arrangement. Additionally he advises on directors’ duties and general corporate governance issues.
Originally from the UK, Ben is also admitted as a lawyer in England and Wales.
Over the Wire Holdings Limited, OtherLevels Holdings Limited, Anatara Lifesciences Limited, and Delta SBD Limited.
Corporate Travel Management
Advised on the $43.7 million acquisition of Chambers Travel (UK/Europe) and $8.9 million acquisition of Diplomat Travel (USA), coupled with a $45.5 million renounceable entitlement offer.
Secondary capital raisings
Viralytics Limited, Tissue Therapies Limited, Invion Limited, Centrepoint Alliance Limited, Imugene Limited and King Island Scheelite Limited.
Centrepoint Alliance Limited
Advised on an acquisition scheme of arrangement to acquire the minority holdings in two dealer group businesses.
Biolife Science Qld Ltd
Acted on back door listing into ASX listed Imugene Limited and Pathway Oncology Pty Ltd into ASX listed Virax Holdings Limited.
Advising on the $502 million acquisition of Viralytics Limitedby Merck by scheme of arrangement.
River City Labs
Advised on the sale of River City Labs Group to Australian Computer Society (ACS).